Since the introduction of combination anti-retroviral therapy (cART) in 1996, the epidemiology of HIV related morbidity and mortality has changed. The incidence of AIDS-defining malignancies such as Kaposi's Sarcoma and certain types of non Hodgkin's lymphoma [1,2] has declined and the mortality rate of HIV-infected individuals from associated opportunistic infections has decreased by 70% [3]. However, evidence suggests that there has been no significant decrease in risk of human papilloma virus (HPV)-related cancers [4,5].
http://ift.tt/2ntd9VA
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου